Jeniece Waite

Labcorp welcomes the U.K.’s commitment to non-animal technologies through targeted investment. Together, we’re advancing regulatory science that emphasizes ethical and innovative safety testing methods. See how we’re supporting this strategy: https://lnkd.in/gYwMqd3k

5

Over the last six months, I’ve interviewed more than 60 marketing professionals spanning Product Manager through C‑suite, across biotech startups and large pharma, and across multiple therapeutic areas (oncology, immunology, rare disease, and more). Here’s what the market is showing: • Most top talent remains passive — not actively applying, but open to the right opportunity • The landscape is highly competitive — fewer openings mean companies must move fast and pitch well to secure marketers • Compensation continues to rise — life sciences base salaries increased by ~9% from 2023 to 2024 • In 2025, salary increase budgets are expected to be more modest (3.5–4%), but candidates with specialized skills and experience still command premium offers • Therapeutic areas like immunology and oncology are especially competitive, with demand outpacing supply • Strong cross-functional influence, launch planning experience, and digital strategy skills are among the most in-demand • Flexibility still matters — hybrid models are expected even at the senior level, especially in key hubs like Boston, NJ, and NYC If you’re hiring in branded pharma or biotech marketing, or considering a move yourself, I’d be happy to connect and share deeper insights on talent trends, compensation expectations, and hiring benchmarks.

12

Regeneron’s move to partner with Tessera feels like a calculated step toward building a greater genetic medicines franchise. The $150 million upfront is notable, but the more important signal is the 50/50 cost and profit share. TSRA-196 gives Regeneron a shot at a true one-time treatment for AATD, and Tessera’s gene-writing approach offers a differentiated path that avoids some of the limitations seen in viral vectors and traditional editing tools. For Regeneron, this is about owning optionality in a space where durable interventions will reshape how value is created. The next year will tell us whether the science can support the strategic ambition. Link: https://lnkd.in/eQD8A_zt

10

In the rapidly evolving landscape of biotechnology, finding and retaining top talent is crucial for staying competitive. Our latest case study showcases how SRG partners with a leading biotechnology company to deliver specialized talent solutions tailored to their dynamic needs. Read about how our quick turnaround satisfied an immediate need for QA shop floor resources by providing 12 top-tier candidates within just 24 hours. We can do this for you, too! From targeted talent sourcing to creating an enhanced candidate experience, SRG's comprehensive approach is driving innovation and growth in the biotech sector. Read the full case study to learn more about our successful collaboration and the impact of our talent solutions. Read More: https://lnkd.in/em2PDXcS #Biotechnology #TalentSolutions #Innovation #Growth

5

1 Comment

Retention issues are critical, but they go beyond the traditional reasons such as recognition, work/life, etc. It goes to the core of employee-empowerment. People don't live and breath the company they work for anymore. They live and breath the WORK, just not the employer. Giving altruistic career ambitions, scientific ambitions, or, for lack of a better term, a bright light at the end of the tunnel to seek, is even more important given the market climate. #CGT #cdmo #hiring #retention #recruiting

6

2 Comments

Most CDMOs struggle to find Quality leaders. Why ? What’s happening in the market right now Hiring is picking up again across Cell & Gene Therapy and Biologics CDMOs. All the big name CDMOs are looking at Quality leaders and they're all fishing in the same small pond. At the same time, candidates are more cautious. Risk appetite is down. Decision cycles are longer. That combination makes mistakes expensive. Where CDMOs go wrong - Hiring on CV. Firing on behaviours. This is the pattern we see repeatedly. Deep technical CVs get prioritised Big company logos get over-weighted “They’ve done the job before” becomes the comfort blanket Then 6–12 months later, things unravel. Why? Because Quality leadership in a CDMO is different The best Quality leaders today aren’t just strong technically. They’re: Decisive under pressure Commercially aware in client-facing environments Articulate and confident with regulators and customers Executors, not consensus seekers Comfortable leading cultural and behavioural change, not just systems These traits rarely show up clearly on a CV. Add fuel to the fire Increased competition between CDMOs for the same people Restructuring across parts of the CGT space, creating quiet openness among passive leaders Limited relocatable talent and shallow networks beyond the usual names The opportunity CDMOs that get this right are shifting focus: Combination of pedigree and behaviour From job history to decision-making style From “can they run Quality?” to “can they lead Quality here?” That’s where the real differentiation now sits. Context is king. If you’re building Quality leadership in a CDMO, this is the moment to rethink how you assess and shortlist talent. #CDMO #Quality #QualityLeadership

62

6 Comments

The right talent isn’t just a hire — it’s a competitive advantage. At Novo Consulting Group LLC, we specialize in recruiting top-tier professionals within FDA-regulated industries, including: ✔ Pharmaceutical ✔ Biotechnology ✔ Medical Devices ✔ Life Sciences We focus on critical roles in: • Validation (CSV, CQV, Equipment, Process) • Quality Assurance & Regulatory Compliance • Automation & Manufacturing • Engineering & Technical Operations • Supply Chain & Procurement Our approach is consultative — not transactional. We understand compliance-driven environments, strict regulatory timelines, and the importance of placing professionals who can deliver from day one. Whether you’re scaling a project, preparing for an audit, or expanding operations — we align the right technical talent with your operational goals. If you’re hiring or exploring your next opportunity in a regulated industry, let’s connect. 📩 jrodriguez@novo-pr.com #NovoConsultingGroupLLC #Recruiting #LifeSciences #Pharma #MedicalDevices #Validation #Quality #Engineering

5

Big boost for U.S. pharma! 🏭🇺🇸 AbbVie is investing $195M to build a new API plant in Illinois, part of a massive $10B commitment to power next-generation therapies. Could this supercharge domestic innovation and bolster medicine security? 💊🔬💡✨ "This investment will help us maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines." – AbbVie spokesperson #Pharma #Manufacturing #Innovation #DrugDiscovery #HealthTech #LifeSciences #Biotech 💪🧬📈⚙️ Source: https://lnkd.in/eVhZhkTD

1

Bristol Myers Squibb has just unveiled a major milestone by opening their new radiopharmaceutical manufacturing facility in Indianapolis. This state-of-the-art complex is a game-changer for cancer treatment and represents a significant step forward in using radiopharmaceuticals for targeted therapies. Key highlights: - 🌟 The facility is the result of a $4.1 billion acquisition of RayzeBio in December 2023. - 📏 Spanning 77,000 square feet and costing $160 million, it focuses on producing next-generation cancer treatments using actinium-225 (Ac225). - 🧬 The plant produces isotopes and drug products, offering greater stability and targeted treatment with minimal side effects. - 💡 RayzeBio's leading candidate, RYZ101, is in Phase 3 trials for gastroenteropancreatic neuroendocrine tumors and early-stage development for small cell lung cancer. This facility not only solidifies BMS's commitment to oncology but also underscores the potential of radiopharmaceuticals in revolutionizing cancer care. With a $40 billion investment pledge in the U.S. over the next five years, it's clear that the future of cancer treatment is incredibly promising. #Oncology #Radiopharmaceuticals #HealthcareInnovation

1

Career growth in life sciences doesn’t always mean “up.” Sometimes it means: ➡️ Broader scope ➡️ New modality exposure ➡️ Stronger mentorship ➡️ A better mission fit How do you define career progress right now? #career #growth #science

7

1 Comment

AstraZeneca’s experimental C5-inhibiting nanobody, gefurulimab, successfully met all primary and secondary endpoints in a 26-week Phase 3 trial for generalized myasthenia gravis—showing significant symptom improvement, strong safety and tolerability with convenient once-weekly self‑administration, positioning it as a potential $1–3 billion blockbuster and prompting upcoming regulatory discussions! https://lnkd.in/eMwT_4Rr

6

💡 The life sciences hiring market hasn’t slowed - it’s become more targeted. What we are seeing right now across pharma and biotech: 🧪 #BigPharma is prioritizing efficiency Headcount growth is selective, but roles tied to revenue protection, compliance, and launch readiness are moving. Think regulatory strategy, HEOR, medical writing, and commercial excellence. 🧫 #Biotech is operating with discipline Smaller teams, sharper mandates. Hiring is tightly linked to clinical milestones, data readouts, and investor confidence. Every role has to earn its seat. Meanwhile, some clear patterns are emerging: 👉 Hybrid profiles are winning (scientific depth + regulatory fluency) 👉 Interview processes are longer - but more intentional 👉 Candidates are doing their homework and asking better questions For job seekers: 🎯 Clarity beats volume. Know your value and articulate it crisply. 🎯 Relationships matter more than ever - warm intros open doors faster than applications. For hiring leaders: ⏱️ When the right person shows up, don’t over-optimize. The best candidates aren’t waiting around. The market isn’t easy - but it is full of opportunity if you know how to read the signals. #biotechjobs #pharmajobs #hiring #talentmarket

32

4 Comments

🌐 Key CRO Industry Trends 2025 shared by Gary Ellsworth, VP & Head of North America Alliance Management, IQVIA in Contract Pharma article: 🚀 EBPs on the rise – 63% of trial starts driven by emerging biopharma, needing CRO support from design ➝ commercialization. 🏢 Mid-sized pharma - Filling resource gaps with tailored CRO partnerships. 🇨🇳 China’s growing role - 30% of trial starts; strong licensing & partnership opportunities. ⚡ Efficiency focus - Reducing “white space” between phases with AI, decentralized trials, & real-world evidence. 🧬 Therapeutic priorities - Oncology, neurology, immunology, & cardiovascular dominate; obesity R&D booming 📈. 💻 Decentralized trials - Expanding patient access while ensuring quality & empathy. 📊 Data complexity - Tripling over the past decade, driving demand for connected, standards-based strategies. 🤝 The future of drug development will depend on strategic sponsor–CRO partnerships to navigate complexity and deliver innovative therapies faster. 🔗 Full Article: https://lnkd.in/gdF2S6nM #ClinicalTrials #CRO #Biopharma #DrugDevelopment #Outsourcing #IQVIA

11

1 Comment

From a recruiter’s perspective in the US life sciences market, 2026 feels different - in a good way.👍 Biotech and pharma companies are more focused, more intentional, and clearer about what talent actually drives value. That means fewer “nice-to-have” roles and more mission-critical hires. We’re seeing strong activity in: • Clinical development leadership • Regulatory affairs • Manufacturing scale-up • AI/data-driven biology If you’re building teams or considering your next career move in biotech or pharma, this is a year to be proactive - not reactive.😉 #Biotech #Pharma #LifeSciencesRecruiter #HiringTrends #2026

22

Large firms bring scale. Boutique firms bring signal. In life sciences recruiting, nuance matters: • Regulatory pathway experience • Modality expertise • Phase-specific leadership • Scientific credibility We don’t just scan resumes, we understand pipelines, platforms, and pressure points. In highly specialized markets, precision beats volume. #precision #lifesciences

8

3 Comments

👨‍🔬💬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲: 𝟐𝐧𝐝 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓 👩‍🔬💬 🧬 Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, its investigational gene therapy for Friedreich’s ataxia (FA). SGT-212 uses a dual direct intradentate nucleus (IDN) and intravenous (IV) infusion approach to deliver the full-length frataxin gene, aiming to restore therapeutic protein levels and address neurological, cardiac, and systemic symptoms of FA. 🦠 NorthX Biologics and Mendus AB announced achieving GMP certification for manufacturing vididencel, Mendus’ lead cell therapy for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). This milestone follows a strategic alliance formed in 2023 to establish scalable, GMP-compliant cell therapy production in Sweden. The collaboration enabled tech transfer and clinical-grade batch production, supporting Mendus’ late-stage trials and commercialization plans. 🧬 Regeneron partnered with Tessera Therapeutics to co-develop TSRA-196, an in vivo gene writing therapy for alpha-1 antitrypsin deficiency (AATD). Regeneron will invest $150M in equity and upfront payments for 50% global rights, with Tessera eligible for $125M in milestones, bringing the deal value to $275M. If successful, TSRA-196 could become the first disease-modifying therapy for AATD, a market projected to grow from $1.2B in 2023 to $3.48B by 2031. 🦠 Longeveron reported Phase 2 CLEAR-MIND trial results showing its stem cell therapy, laromestrocel, reduced neuroinflammation in patients with mild Alzheimer’s disease compared to placebo. The therapy demonstrated durable improvements across 13 of 14 brain regions, notably the hippocampus, using diffusion tensor imaging and free water analysis at week 39. 🧬 Ensoma announced dosing the first patient in its Phase 1/2 trial of EN-374, an in vivo hematopoietic stem cell (HSC)-directed gene insertion therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder causing severe infections. EN-374 uses virus-like particles to deliver a CYBB transgene to HSCs, aiming to restore NADPH oxidase function and immune defense through a one-time treatment. The trial will assess safety, tolerability, and preliminary efficacy, with adult cohorts followed by pediatric enrollment. 🦠 NextCell Pharma AB partnered with OptiCell Solutions AB to enhance cell handling, freezing, storage, and transport for research and development purposes. Under the agreement, OptiCell will manage donor and customer relations, including apheresis operations at its Huddinge clinic, while NextCell oversees cell processing and logistics. Revenue from these services will support development of ProTrans™, NextCell’s lead candidate for type 1 diabetes. 🛎 My aim is to be the messenger when it comes to your CGT news. Follow #mCGT to stay updated! #celltherapy #genetherapy #ATMP #advancedtherapy

67

YAY! 3rd year in a row! At PPD Search, we know that candidate experience relates to finding, hiring and retaining talent. The on-boarding process takes place immediately following us briefing candidates on opportunities. The statistics around poor candidate experience would make you cringe. Did you know that 56% of candidates would discourage others from applying due to a bad recruiting experience? Candidates have higher expectations than ever, and a slow or frustrating hiring process can send them straight to a competitor and you may even lose them as customers. We know that even if they take the job, they do not forget about the hiring process and are left wondering "is this the right place for me?", it only takes a few other niggly negative things to happen in the first 90 days to reinforce in their mind that the hiring experience aligns with their on-boarding, which if not strong, the new employee starts looking for another job, in fact 84% of the Australian workforce has stated that they are either looking for a new role or open to opportunities that might be presented to them. #onboarding #culture #candidateexperience

34

2 Comments